Prognostic Model of Shulman and Benaim for Event-Free Survival (EFS) in a Man with Androgen-Independent Prostate Carcinoma

Description

Shulman and Benaim developed a prognostic model for event-free survival (EFS) in men with androgen-independent prostate cancer. This can help identify patients who may benefit from more aggressive management. The authors are from the University of Texas Southwestern Medical Center and the Veterans Affairs Hospital in Dallas.

Patient selection: prostate cancer with disease progression during androgen deprivation therapy

Model: derived by recursive partitioning analysis

Parameters:

(1) metastatic prostate cancer at time of diagnosing androgen-independent disease progression

(2) time to PSA recurrence

(3) PSA doubling time

PSA Doubling Time	Metastatic Disease	Time to PSA Recurrence	Risk Group
> 10 months	NA	NA	low
<= 10 months	absent	NA	intermediate
<= 10 months	present	> 13 months	intermediate
<= 10 months	present	<= 13 months	high

Risk Group	Mean EFS in months	Mean Number of Bone Events
low	96 months	0.3
intermediate	34 (28 - 43) months	0.7
high	6 months	1.4

To read more or access our algorithms and calculators, please log in or register.

Prognostic Model of Shulman and Benaim for Event-Free Survival (EFS) in a Man with Androgen-Independent Prostate Carcinoma

Description

Specialty